Terms ending in 2032
Every in-force patent on Epicentrx, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,139,519 | Organonitro Thioether Compounds and Medical Uses Thereof In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 9,468,625 | Organonitro Thioether Compounds and Medical Uses Thereof In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 8,664,247 | Acyclic Organonitro Compounds for Use in Treating Cancer In force · High confidence | Northrop Grumman Systems Corporation | In force | High confidence | |
| US 11,660,286 | Methods and Compositions Comprising a Nitrite-Reductase Promoter for Treatment of Medical Disorders and Preservation of Blood Products In force · High confidence | Epicentrx, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Epicentrx, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.